NovaBay Operating Cycle from 2010 to 2026

NBY Stock  USD 9.46  1.18  11.09%   
NovaBay Pharmaceuticals Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 108.30 in 2026. During the period from 2010 to 2026, NovaBay Pharmaceuticals Operating Cycle regression line of annual values had r-squared of  0.14 and arithmetic mean of  275.66. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
114
Current Value
108.3
Quarterly Volatility
267.21433015
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 253.5 K, Interest Expense of 531.4 K or Other Operating Expenses of 17 M, as well as many indicators such as Price To Sales Ratio of 0.23, Dividend Yield of 0.0 or Days Sales Outstanding of 15.86. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with NovaBay Stock
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of NovaBay Pharmaceuticals over the last few years. It is NovaBay Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

NovaBay Operating Cycle Regression Statistics

Arithmetic Mean275.66
Geometric Mean139.07
Coefficient Of Variation96.94
Mean Deviation190.83
Median169.93
Standard Deviation267.21
Sample Variance71,403
Range1.1K
R-Value(0.37)
Mean Square Error65,567
R-Squared0.14
Significance0.14
Slope(19.74)
Total Sum of Squares1.1M

NovaBay Operating Cycle History

2026 108.3
2025 114.0
2024 99.13
2023 266.74
2022 240.5
2021 378.9
2020 96.54

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 114.00  108.30 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.